IDEXX LaboratoriesFRA:IX1 -0.19%96 Net Margin % is 24.41% as of Mar. 2026, which is 17% above its 10-year median of 20.83. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €552.99 (Modestly Undervalued). Among 204 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 95.59% on this metric.
The historical rank and industry rank for IDEXX Laboratories's Net Margin % or its related term are showing as below:
FRA:IX1'
s Net Margin % Range Over the Past 10 Years
Min: 12.51 Med: 20.83 Max: 24.63
Current: 24.63
FRA:IX1's Net Margin % is ranked better than 95.59% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs FRA:IX1: 24.63
IDEXX Laboratories (FRA:IX1) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
IDEXX Laboratories Net Margin % Related Terms
IDEXX Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a Net Margin % of 24.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on IDEXX Laboratories and its competitors. This is 17% above median its historical median of 20.83. Over the past decade, IDEXX Laboratories' Net Margin % has ranged from 12.51 to 24.63. According to the industry distribution chart, IDEXX Laboratories ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 4.4%.
Is IDEXX Laboratories' Net Margin % too high?
IDEXX Laboratories' current Net Margin % of 24.41% is 17% above median its 10-year median of 20.83. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 24.63. Based on the distribution chart, IDEXX Laboratories ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Net Margin % compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #9 out of 204 companies for Net Margin %. This places IDEXX Laboratories in the top 4% of its industry — outperforming the majority of peers. Historically, IDEXX Laboratories' own Net Margin % has ranged from 12.51 to 24.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Net Margin % is 24.41%, which is 17% above median its own 10-year median of 20.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current Net Margin % is 24.41%, which is 17% above median its 10-year median of 20.83. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Net Margin % is 24.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Net Margin %: 24.41% (17% above median its 10-year median of 20.83)
GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
